Thematic Exposure -- 6/10
Merck is thematically exposed to the single largest secular growth market in healthcare -- oncology and
immuno-oncology -- through the dominant franchise (Keytruda, ~$31.6B in 2025, ~49% of total revenue).
The company commands ~55-60% of the global PD-1/PD-L1 checkpoint inhibitor market, roughly 3x its nearest
competitor. Winrevair adds a genuine new growth vector in PAH with a $1.9B annualized run-rate. However,
the Keytruda LOE in 2028-2029 represents the largest single-product patent cliff in pharmaceutical history,
with ~$24B of annual revenue at risk. Gardasil China impairment (-39% YoY) further erodes the
diversification story. The ADC pipeline and SC Keytruda formulation are credible offsets but carry execution
risk and are years from fully replacing revenue at risk.
Weight: 25%
PD-1/PD-L1 Market Share
~55-60%
Keytruda -- dominant global franchise
Keytruda 2025 Revenue
$31.6B
+7.3% YoY -- 48.7% of total revenue
Winrevair Run-Rate
~$1.9B
Q4 2025 annualized -- first-in-class PAH
Keytruda LOE
2028
Largest single-product cliff in pharma
Oligopoly Gate: PASS -- Dominant PD-1/PD-L1 Checkpoint Inhibitor
~55-60% Global PD-1/PD-L1 Share -- 2.5-3x Nearest Competitor -- But Time-Limited by 2028 LOE
Clear dominance: Keytruda is the dominant PD-1 checkpoint
inhibitor globally with ~$31.6B in 2025 revenue, approximately 2.5-3x the size of its nearest
competitor (Opdivo at ~$9-10B, BMS). The PD-1/PD-L1 market is effectively a duopoly at the top,
with Keytruda holding approvals across 20+ indications and serving as the global standard of care
in first-line NSCLC, the largest oncology indication by patient volume.
Massive TAM: The global checkpoint inhibitor market is ~$48.5B (2025), growing toward $73B by 2030. Merck captures the majority of this TAM and continues to expand label across indications.
Time-limited moat: Core compound patent expires 2028, with method-of-use patents potentially extending to 2029. This dominance carries the largest single-product LOE risk in pharma history. SC Keytruda patents could extend exclusivity to 2042, but conversion is still early.
Massive TAM: The global checkpoint inhibitor market is ~$48.5B (2025), growing toward $73B by 2030. Merck captures the majority of this TAM and continues to expand label across indications.
Time-limited moat: Core compound patent expires 2028, with method-of-use patents potentially extending to 2029. This dominance carries the largest single-product LOE risk in pharma history. SC Keytruda patents could extend exclusivity to 2042, but conversion is still early.
| Drug | Company | Est. 2025 Revenue | PD-1/PD-L1 Share |
|---|---|---|---|
| Keytruda | Merck | ~$31.6B | ~55-60% |
| Opdivo | BMS | ~$9-10B | ~17-19% |
| Imfinzi | AstraZeneca | ~$4-5B | ~8-10% |
| Tecentriq | Roche | ~$3-4B | ~6-8% |
| Others (incl. China PD-1s) | Various | ~$5-6B | ~10-12% |
Oligopoly PASS with ~55-60% share. Keytruda is the clear category leader across 20+ approved indications.
Global checkpoint inhibitor market ~$48.5B growing toward $73B by 2030.
Revenue Mix by Product (2025 Full Year, Daloopa)
| Product / Segment | 2025 Revenue | % of Total | YoY Growth |
|---|---|---|---|
| Keytruda (PD-1 oncology) | $31,640M | 48.7% | +7.3% |
| Animal Health | $6,354M | 9.8% | +8.1% |
| Gardasil (HPV vaccine) | $5,233M | 8.0% | -39.0% |
| Winrevair (PAH) | $1,443M | 2.2% | +244% |
| Lagevrio (COVID antiviral) | $380M | 0.6% | -61% |
| Other Pharma | ~$19,961M | 30.7% | -- |
| Total | $65,011M | 100% | +1.3% |
Keytruda represents nearly half of total revenue -- the highest single-product concentration of any
major pharma company. Gardasil decline (-39%) driven by China domestic competition. Winrevair is the
standout launch with +244% growth. Calendar FY. Data sourced from Daloopa.
Theme 1: Oncology / Checkpoint Inhibitor Dominance (Strong Positive)
$31.6B Keytruda Revenue -- ~55-60% PD-1 Share -- Standard of Care in First-Line NSCLC
Category leadership: Keytruda holds approvals across 20+
indications and is the global standard of care in NSCLC first-line, the largest oncology indication
by patient volume. Revenue grew +7.3% in 2025 to $31.6B despite approaching LOE, demonstrating
continued label expansion and market penetration.
TAM growth: The global checkpoint inhibitor market is ~$48.5B (2025), growing toward $73B by 2030. Merck captures the majority of this TAM through Keytruda, with further expansion into adjuvant and neoadjuvant settings adding patient populations.
Concentration risk: At 48.7% of total revenue, this is the highest single-product concentration of any major pharma company. The dominance is real, but it creates an existential dependency on one franchise -- see Theme 5.
TAM growth: The global checkpoint inhibitor market is ~$48.5B (2025), growing toward $73B by 2030. Merck captures the majority of this TAM through Keytruda, with further expansion into adjuvant and neoadjuvant settings adding patient populations.
Concentration risk: At 48.7% of total revenue, this is the highest single-product concentration of any major pharma company. The dominance is real, but it creates an existential dependency on one franchise -- see Theme 5.
Theme 2: Winrevair / PAH Launch (Strong Positive, Early)
First-in-Class PAH Therapy -- $1.9B Annualized Run-Rate -- $3-5B Peak Sales Potential
Exceptional launch trajectory: Winrevair (sotatercept) is a
first-in-class activin signaling inhibitor for PAH, launched March 2024. The revenue ramp has been
one of the strongest specialty launches in recent pharma history: Q2 2024 $70M (launch quarter),
Q4 2024 $200M, Q4 2025 $467M (quarterly run-rate approaching ~$1.9B annualized).
Disease-modifying differentiation: Winrevair is the only disease-modifying agent approved for PAH, giving it a differentiated mechanism vs. legacy vasodilator therapies. The FDA expanded its label based on the Phase III ZENITH study (reduced risk of clinical worsening in WHO FC II-IV). EU CHMP has also recommended expanded use.
TAM opportunity: The 7MM PAH market is projected at ~$9.3B by 2034. With no meaningful competition in its mechanism class today, the bull case is $3-5B peak sales. This is a genuine pipeline-to-revenue success story and a critical building block for post-LOE Merck.
Disease-modifying differentiation: Winrevair is the only disease-modifying agent approved for PAH, giving it a differentiated mechanism vs. legacy vasodilator therapies. The FDA expanded its label based on the Phase III ZENITH study (reduced risk of clinical worsening in WHO FC II-IV). EU CHMP has also recommended expanded use.
TAM opportunity: The 7MM PAH market is projected at ~$9.3B by 2034. With no meaningful competition in its mechanism class today, the bull case is $3-5B peak sales. This is a genuine pipeline-to-revenue success story and a critical building block for post-LOE Merck.
Q2 2024 (Launch)
$70M
First commercial quarter
Q4 2024
$200M
Rapid sequential ramp
Q4 2025
$467M
~$1.9B annualized run-rate
Peak Sales Potential
$3-5B
Bull case -- first-in-class PAH
Theme 3: Gardasil / Vaccines (Challenged)
-39% YoY Revenue Decline -- China Domestic Competition Is Structural -- Ex-China Stable
China collapse: Gardasil revenue fell from $8.6B (2024) to $5.2B
(2025), a -39% decline driven almost entirely by China. China accounted for 60-70% of Gardasil ex-US
sales historically. Domestic Chinese 9-valent HPV vaccines (Innovax Cecolin 9) launched at a ~60%
price discount, triggering channel inventory destocking and cancelled shipments.
Structural, not cyclical: Domestic Chinese competitors will permanently compress pricing and share. Merck has responded with male indication approval in China (2025) and price concessions, but this is damage mitigation, not recovery.
Ex-China stability: The ex-China Gardasil franchise remains stable with secular tailwinds (HPV vaccination rates still rising globally). But the largest growth market has been permanently impaired.
Structural, not cyclical: Domestic Chinese competitors will permanently compress pricing and share. Merck has responded with male indication approval in China (2025) and price concessions, but this is damage mitigation, not recovery.
Ex-China stability: The ex-China Gardasil franchise remains stable with secular tailwinds (HPV vaccination rates still rising globally). But the largest growth market has been permanently impaired.
Gardasil 2024
$8.6B
Prior year baseline
Gardasil 2025
$5.2B
-39% YoY -- China-driven
China Price Discount
~60%
Domestic 9-valent competitors
Theme 4: ADC Pipeline (Promising but Pre-Revenue)
$22B+ Invested in ADC Partnerships -- Pre-Revenue -- Clinical Readouts 2026-2028
Daiichi Sankyo partnership: $22B deal for 3 DXd-based ADCs
(HER3-DXd, I-DXd, R-DXd), expanded to 4 candidates. This is the largest ADC partnership in the
industry and positions Merck with access to the leading ADC platform technology.
Kelun-Biotech partnership: $175M upfront for 7 preclinical ADCs, broadening the ADC portfolio beyond the Daiichi platform. The ADC market is growing at ~16% CAGR, from $6.5B (2024) to ~$16B (2030).
Pre-revenue risk: These are pipeline-stage assets. Clinical readouts will be key over 2026-2028. The ADC theme is directionally positive -- Merck has secured access to leading platforms -- but revenue contribution is 3-5 years away and binary clinical risk remains.
Kelun-Biotech partnership: $175M upfront for 7 preclinical ADCs, broadening the ADC portfolio beyond the Daiichi platform. The ADC market is growing at ~16% CAGR, from $6.5B (2024) to ~$16B (2030).
Pre-revenue risk: These are pipeline-stage assets. Clinical readouts will be key over 2026-2028. The ADC theme is directionally positive -- Merck has secured access to leading platforms -- but revenue contribution is 3-5 years away and binary clinical risk remains.
Daiichi Sankyo Deal
$22B
4 DXd-based ADC candidates
Kelun-Biotech Deal
$175M
7 preclinical ADC candidates
ADC Market CAGR
~16%
$6.5B (2024) to ~$16B (2030)
Theme 5: Keytruda LOE / Patent Cliff (The Dominant Risk)
Core Patent Expires 2028 -- 49% of Revenue at Risk -- Largest Single-Product LOE in Pharma History
Scale of the cliff: Keytruda = 48.7% of total revenue ($31.6B
of $65B). Without mitigation, estimated ~80% revenue erosion post-LOE, or ~$24B annual revenue loss.
The core compound patent expires 2028, with method-of-use patents potentially extending to 2029.
This is the defining thematic risk for MRK and arguably the largest single-product LOE in
pharmaceutical history.
SC Keytruda mitigation: Subcutaneous Keytruda has been approved, with SC patents that could extend exclusivity to 2042. Management targets 30-40% SC conversion of the US patient base by 2027, which could preserve $9-12B/year of revenue. This is credible but unproven at the scale required.
Management outlook: Management claims line of sight to "$70B+ of commercial opportunity by mid-2030s" vs. consensus peak Keytruda of ~$35B. The 2028-2031 period will be a revenue trough regardless. This is the single biggest overhang on the thematic score.
SC Keytruda mitigation: Subcutaneous Keytruda has been approved, with SC patents that could extend exclusivity to 2042. Management targets 30-40% SC conversion of the US patient base by 2027, which could preserve $9-12B/year of revenue. This is credible but unproven at the scale required.
Management outlook: Management claims line of sight to "$70B+ of commercial opportunity by mid-2030s" vs. consensus peak Keytruda of ~$35B. The 2028-2031 period will be a revenue trough regardless. This is the single biggest overhang on the thematic score.
| LOE Factor | Assessment |
|---|---|
| Core Patent Expiry | 2028 -- compound patent; method-of-use may extend to 2029 |
| Revenue at Risk | ~$24B/year -- ~80% erosion post-LOE without mitigation |
| SC Keytruda Patents | Extend to 2042 -- targets 30-40% US conversion by 2027 |
| SC Revenue Preservation | $9-12B/year -- credible but unproven at scale |
| Management Mid-2030s Target | $70B+ commercial opportunity -- aspirational, requires flawless execution |
| Revenue Trough Period | 2028-2031 -- unavoidable regardless of mitigation |
The 2028 LOE is the single largest risk to the investment thesis. SC Keytruda and pipeline diversification
are credible offsets but cannot fully replace $31.6B in revenue within the trough period.
Theme 6: Animal Health (Steady, Non-Thematic)
$6.4B Revenue -- ~10% of Total -- Mid-Single-Digit Growth -- Diversification, Not a Catalyst
Stable contributor: Animal Health ($6.4B, ~10% of revenue) grew
+8.1% YoY in 2025. Companion animal trends are secularly positive. This provides meaningful
diversification and steady cash flow, but it is not a thematic catalyst and will not materially offset
the Keytruda LOE.
Score Rationale
| Factor | Assessment | Impact |
|---|---|---|
| Keytruda oncology dominance | Clear oligopoly leader (~55-60% PD-1 share) | +2 |
| Oncology TAM growth | ~$48.5B growing to $73B by 2030 | +1 |
| Winrevair launch trajectory | First-in-class, $1.9B run-rate, $3-5B peak potential | +1.5 |
| ADC pipeline optionality | $22B+ invested, pre-revenue, clinical risk | +0.5 |
| Gardasil China impairment | -39% YoY, structural competitive threat | -1 |
| Keytruda LOE 2028-2029 | 49% of revenue at risk, largest LOE in pharma history | -2 |
| SC Keytruda mitigation | Credible but unproven at scale; preserves $9-12B scenario | +0.5 |
| Animal Health stability | Steady but non-thematic | +0 |
| Portfolio breadth post-LOE | $70B opportunity claim vs. $35B peak Keytruda -- aspirational | +0.5 |
6/10 — MRK scores a 6 reflecting strong
current positioning in a massive TAM (oncology), genuine new launch momentum (Winrevair), but a
time-limited franchise dominance with the largest single-product cliff in industry history approaching
in ~2 years.
The score is shaped by the tension between current dominance and approaching LOE:
(a) Oligopoly passed but time-limited. ~55-60% global PD-1/PD-L1 share with 20+ approved indications. This is clear category leadership today -- but the core patent expires 2028.
(b) Winrevair is a genuine success. The launch trajectory ($70M to $467M/quarter in 18 months) and first-in-class status in PAH make this one of the best specialty launches in recent pharma history. Bull case $3-5B peak sales provides meaningful but incomplete LOE offset.
(c) Gardasil impairment reduces diversification. The -39% China-driven decline removes what was a significant growth pillar. Ex-China remains stable but the franchise is materially smaller than it was 18 months ago.
(d) The LOE dominates the forward outlook. ~$24B of annual revenue at risk. SC Keytruda and the ADC pipeline are credible but cannot fully bridge the 2028-2031 trough. This is the primary reason the score stays at 6 despite strong current positioning.
Why 6 and not higher: The 2028 LOE is the largest single-product patent cliff in pharma history. Nearly half the company revenue is at risk, and the mitigation strategies (SC conversion, ADC pipeline, Winrevair ramp) are credible but collectively insufficient to prevent a multi-year revenue trough. Gardasil China adds a second negative thematic overlay.
Why not lower: Current oncology dominance is real and massive ($31.6B). The TAM is growing toward $73B. Winrevair is a genuine first-in-class success. The ADC pipeline via Daiichi Sankyo provides optionality. SC Keytruda could preserve $9-12B/year. The building blocks exist -- execution is the question.
The score is shaped by the tension between current dominance and approaching LOE:
(a) Oligopoly passed but time-limited. ~55-60% global PD-1/PD-L1 share with 20+ approved indications. This is clear category leadership today -- but the core patent expires 2028.
(b) Winrevair is a genuine success. The launch trajectory ($70M to $467M/quarter in 18 months) and first-in-class status in PAH make this one of the best specialty launches in recent pharma history. Bull case $3-5B peak sales provides meaningful but incomplete LOE offset.
(c) Gardasil impairment reduces diversification. The -39% China-driven decline removes what was a significant growth pillar. Ex-China remains stable but the franchise is materially smaller than it was 18 months ago.
(d) The LOE dominates the forward outlook. ~$24B of annual revenue at risk. SC Keytruda and the ADC pipeline are credible but cannot fully bridge the 2028-2031 trough. This is the primary reason the score stays at 6 despite strong current positioning.
Why 6 and not higher: The 2028 LOE is the largest single-product patent cliff in pharma history. Nearly half the company revenue is at risk, and the mitigation strategies (SC conversion, ADC pipeline, Winrevair ramp) are credible but collectively insufficient to prevent a multi-year revenue trough. Gardasil China adds a second negative thematic overlay.
Why not lower: Current oncology dominance is real and massive ($31.6B). The TAM is growing toward $73B. Winrevair is a genuine first-in-class success. The ADC pipeline via Daiichi Sankyo provides optionality. SC Keytruda could preserve $9-12B/year. The building blocks exist -- execution is the question.
Data sourced from Daloopa, Merck public filings and earnings calls (FY 2025), and third-party oncology/pharma market research as of April 2026.